DSM signs manufacturing agreement

Will use XD technology in contract with major pharma company

DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, has signed a contract manufacturing services agreement using its proprietary XD high cell density process technology with a major pharma company.

XD technology is an intensified cell culture process with a titre achievement 5-15 times higher than current standard biomanufacturing processes. DSM says it is widely applicable for multiple products including proteins, fusion proteins and antibodies, and has been successfully employed across the full spectrum of mammalian cell systems.

DSM will complete the process development and commercial manufacturing for the products at its r&d and manufacturing site in Groningen, The Netherlands and at new operations in Brisbane, Australia.

The commercial demand will be met from Brisbane on a 500-litre XD production line. Brisbane is DSM’s blueprint for its ‘biologics plant of the future’ for biopharmaceuticals manufacturing.

DSM Biologics’ president Karen King commented: ‘We are proud to announce that a major pharma company has chosen DSM’s services and technology for three of its leading antibody pipeline projects for different indications.’

Financial terms were not disclosed.

Companies